Autoimmune CAR-T Cell Therapy Market Size, Trend, Revenue Report 2026 to 2035

What is Autoimmune Car-T Cell Therapy Market Size?

Autoimmune Car-T Cell Therapy Market is estimated to grow at a 66.1% CAGR during the forecast period for 2026 to 2035.

Autoimmune Car-T Cell Therapy Market Size, Share & Trends Analysis Distribution by Therapy Platform (Autologous CAR-T, Allogeneic (Off-the-Shelf) CAR-T, In-Vivo CAR-T), By Target Antigen (CD19-Directed CAR-T, BCMA-Directed CAR-T, Dual / Multi-Target CAR-T, Other Targets), By Indication (Neurological Autoimmune Diseases, Rheumatic & Systemic Autoimmune Diseases, Other Immune-Mediated Diseases) and Segment Forecasts, 2026 to 2035

Autoimmune CAR-T cell therapy is an emerging form of cellular immunotherapy that uses genetically modified T cells to treat autoimmune diseases. Unlike conventional CAR-T approaches developed primarily for oncology, these therapies are designed to identify and eliminate disease-driving immune cells, particularly autoreactive B cells that produce pathogenic autoantibodies.

The therapies direct engineered T cells against specific surface antigens, such as CD19 and BCMA, with the goal of interrupting abnormal immune activity and helping to restore immune balance. Development pathways include autologous approaches that use a patient’s own modified T cells, allogeneic (donor-derived) products, and in-vivo methods that reprogramme T cells directly within the body. Clinical investigation is underway across a range of conditions, including systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies, multiple sclerosis and other neurological autoimmune disorders.

The global autoimmune CAR-T cell therapy market encompasses therapeutic development, clinical evaluation, manufacturing and the potential commercialisation of these advanced cellular treatments. Current activity is characterised by a growing pipeline of antigen-specific programmes, with CD19-directed therapies representing a major focus alongside emerging BCMA-targeted and multi-target strategies. Research spans multiple engineering platforms, including viral-vector autologous CAR-T, transient mRNA-based approaches, off-the-shelf allogeneic products and in-vivo CAR-T technologies. As clinical trials expand across rheumatic, neurological and systemic autoimmune indications, the field is progressing from early-stage research toward a broader therapeutic category with potential application across diverse patient populations.

Competitive Landscape

Which are the Leading Players in the Autoimmune Car-T Cell Therapy Market?

• Kyverna Therapeutics, Inc.
• Cabaletta Bio, Inc.
• Cartesian Therapeutics, Inc.
• Autolus Therapeutics plc
• Adicet Bio, Inc.
• Fate Therapeutics, Inc.
• Bioray Laboratories, Inc. (BRL Medicine)
• Bristol Myers Squibb Company
• Novartis AG
• Miltenyi Biomedicine GmbH
• Sana Biotechnology, Inc.
• CRISPR Therapeutics AG
• EdiGene, Inc. 

Market Dynamics

Driver

Increasing demand for effective treatments for refractory autoimmune diseases 

A substantial number of patients with autoimmune disorders continue to experience persistent disease activity, relapses, or inadequate responses despite existing immunosuppressive drugs and biologic therapies. There is therefore a need for more advanced treatment methods which can aim at the immune cells responsible for causing autoimmune reactions. CAR-T cell therapy holds the promise of selectively removing the B cells associated with the disease, especially by means of CD19-directed therapies, and may thus be able to restore the immune system and secure more profound and longer-lasting remissions. Initial clinical results in patients with systemic lupus erythematosus, systemic sclerosis, and inflammatory myopathies have increased interest in this technique, prompting pharmaceutical and biotechnology companies to broaden the clinical development of this approach to other autoimmune conditions.

Restrain/Challenge

High treatment costs and complex CAR-T cell manufacturing 

The development of autoimmune CAR-T cell therapy is hindered by the high cost and complexity involved in manufacturing personalized cell treatments. Producing autologous CAR-T cells involves a number of specialized procedures, such as collecting the T cells, genetically modifying them, expanding the cells, carrying out quality testing, and then reinfusing them, a process that is both time-consuming and demanding in terms of resources. The need for specialized manufacturing facilities, trained staff, and strict quality-control measures also adds to the cost of treatment and reduces access to it. This is especially important in the case of autoimmune diseases, since the group of possible patients in this context is much larger than the small number of patients who at present receive CAR-T therapy for cancer. Even though allogeneic and in-vivo CAR-T technologies are being developed in order to make manufacturing easier and to improve scalability, these methods still encounter technical and clinical difficulties concerning immune rejection, cell persistence, and safety. 

Autologous CAR-T Segment is Expected to Drive the Autoimmune Car-T Cell Therapy Market

Autologous CAR-T is expected to dominate the autoimmune CAR-T cell therapy market, driven by its comparatively advanced clinical development, established therapeutic approach, and expanding clinical evidence across autoimmune disorders. This technique involves taking the patient's own T cells, modifying them genetically so that they can identify the immune cells associated with the disease, expanding them, and then returning them to the patient. Research into CD19-targeted autologous CAR-T therapies is becoming more common in the case of systemic lupus erythematosus, systemic sclerosis, inflammatory myopathies, and neurological autoimmune diseases. Moreover, progress in transient mRNA-engineered autologous CAR-T methods is broadening the range of treatments available by allowing for temporary CAR expression, which in turn provides better control over the activity of the engineered T cells and may lead to an improved safety profile for these therapies.

Dual / Multi-Target CAR-T Segment is Growing at the Highest Rate in the Autoimmune Car-T Cell Therapy Market

The dual / multi-target CAR-T is forecast to show maximum growth in the autoimmune CAR-T cell therapy market due to the growing number of studies focusing on treatments which target several immune-cell populations at once. As opposed to single-target therapies, dual/multi-target CAR-T treatment will target not only one antigen but several antigens that are present in various stages of B cell development, such as CD19 and BCMA, allowing for more effective depletion of autoreactive B cells and plasma cells producing antibodies. Such treatments are becoming more common in the case of autoimmune conditions like systemic lupus erythematosus, systemic sclerosis, and neurological autoimmune diseases when the cells producing antibodies may be a source of pathogenesis.

Why North America Led the Autoimmune Car-T Cell Therapy Market?

The autoimmune CAR-T cell therapy market has been dominated by North America owing to the superior research facilities, developed biotechnology network and clinical development of autoimmune CAR-T therapies in the region. North America enjoys the advantage of having advanced centers of clinical research, advanced manufacturing capacities for CAR-T cells, competent regulatory authorities and investment in cellular immunotherapies. The U.S., which occupies a prominent portion of the overall development activities in the region, has seen many clinical trials of CD19-targeting CAR-T cell therapies being conducted for systemic lupus erythematosus, systemic sclerosis, inflammatory myopathies, and neurological autoimmune diseases. Additionally, good collaboration between biotech firms and hospitals has enabled the transition of experimental CAR-T cell therapy approaches into clinical applications.

Key Development

• May 2026: Kyverna Therapeutics received FDA alignment on the rolling BLA submission pathway for miv-cel (KYV-101), its investigational CD19-directed CAR-T therapy for stiff person syndrome (SPS), and outlined plans for a potential 2027 launch.

Autoimmune Car-T Cell Therapy Market Report Scope: